The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
Dr Thomas C. Krivak highlights key data from the GY018 trial investigating chemotherapy plus pembrolizumab in both dMMR and pMMR advanced endometrial cancer, confirming and extending the findings from the RUBY trial supporting pembrolizumab's approval and use in both dMMR and pMMR populations.
EP: 1.Diagnosing and Staging Patients With Endometrial Cancer
EP: 2.Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer
EP: 3.Shared Decision-Making in Advanced or Recurrent Endometrial Cancer
EP: 4.The Role of dMMR in the Progression of Endometrial Cancer
EP: 5.Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial
Now Viewing
EP: 6.The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
EP: 7.Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
EP: 8.Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer
EP: 9.Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer
EP: 10.Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer
EP: 11.Staging and Biomarker Testing For Patients With Cervical Cancer
EP: 12.Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
EP: 13.Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
EP: 14.Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
EP: 15.Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer
EP: 16.Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer
EP: 17.Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer
Related Videos
Related Content
